Judge Validates Key Mannatech Patents for Technology Related to its Ambrotose® Glyconutrient Products
Boston Mountain Laboratories, Inc. to stop manufacturing all products
infringing on Mannatech patents
COPPELL, TEXAS October 7, 2009 - Mannatech, Incorporated (NASDAQ - MTEX), a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, announced today the company has secured a second injunction in its ongoing efforts to protect its patented glyconutrient products Ambrotose® complex and Advanced Ambrotose™ formula.
The United States District Court for the Northern District of Texas, Dallas Division, has entered a Final Judgment and Permanent Injunction against Boston Mountain Laboratories, Inc., which bans Boston Mountain Laboratories from manufacturing or selling BML Glyconutrient Formula, Glyco-8, Glycoessentials, Glyco-Essence, Glyconutrients, MG-3, and MG-3c for the duration of Mannatech’s U.S. Patents 6,929,807; 7,157,431; 7,196,064; 7,199,104; and 7,202,220.
The courts have recognized that Mannatech is the rightful owner of the patented technology concerning “Compositions of Plant Technology as Dietary Supplements.” As part of the final judgment in this case, Boston Mountain Laboratories, plus its officers, agents, employees, and any persons acting in concert or participation with the company, are prohibited from making, using, selling, or otherwise distributing within the United States any of the accused products or any colorable imitations thereof.
“Mannatech has demonstrated that it will fight to protect its intellectual property. The Court’s decision is further notice to all interested parties that we will do what is necessary to support our products and our independent sales Associates in the field,” said Keith Clark, senior vice president and general counsel of Mannatech.
Mannatech has vigorously pursued patent infringement cases against companies to stop their manufacture and sale of infringing products. The company’s first victory came last year, when Mannatech won on all patent and trademark infringement claims brought against Glycobiotics International, Inc. As part of the final judgment in that case, Glycobiotics was ordered to stop production of its infringing product Glycomannan and deliver any existing product to Mannatech for destruction.
Mannatech has been awarded more than 45 patents in 30 countries on its formulations for plant-based polysaccharide dietary supplements. Using this patented technology, Mannatech has developed and provides a key line of supplements under the trade names Ambrotose complex and Advanced Ambrotose formula through a network of more than 500,000 authorized independent sales Associates worldwide.
Mannatech is a global leader within the wellness industry and a member in good standing of the Council for Responsible Nutrition and the Direct Selling Association. Many of Mannatech’s products are certified by NSF International, an organization within the natural products industry committed to protecting public health and safety. Mannatech also guarantees customer satisfaction; if a customer is not completely satisfied, they can return the product within 180 days for a full refund.
Mannatech, Incorporated develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. These proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore and the Republic of Korea.
For more information please visit https://new.mannatech.com.
Please Note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend,” ”believe,” “expect” or “will allow” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into newinternational markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.
Media Contact Information: